MD. Physician, Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Kayseri City Education and Research Hospital, Kayseri, Turkey.
MD, PhD. Professor, Department of Infectious Disease and Clinical Microbiology, Erciyes Üniversitesi Tıp Fakültesi, Kayseri, Turkey.
Sao Paulo Med J. 2022 Jan-Feb;140(1):12-16. doi: 10.1590/1516-3180.2021.0200.R1.03052021.
Coronavirus disease 2019 (COVID-19) is an ongoing global health threat. However, currently, no standard therapy has been approved for the disease.
To evaluate the clinical effectiveness of convalescent plasma (CP) in patients with acute respiratory distress syndrome (ARDS) due to COVID-19.
Retrospective study conducted at Kayseri City Education and Research Hospital, Kayseri, Turkey.
The case group consisted of adult patients (> 18 years) with ARDS due to COVID-19 who received CP in combination with antiviral and supportive treatment. These patients were compared with others who only received antiviral and supportive treatment.
During the study period, a total of 30 patients with ARDS due to COVID-19 were included. Eleven patients (36%) received CP in combination with antiviral and supportive treatment, whereas nineteen patients (64%) in the control group only received antiviral and supportive treatment. On admission, the median age, demographic and clinical data and initial laboratory test results were similar between the groups (P > 0.05). On the 14th day of treatment, the laboratory values remained similar between the groups (P > 0.05). The mortality rates were not significantly different between the groups.
CP treatment did not affect mortality or lead to clinical improvement for COVID-19 patients with ARDS.
2019 年冠状病毒病（COVID-19）是当前全球面临的一项卫生挑战。然而，目前尚未批准针对该疾病的标准疗法。
评估 COVID-19 所致急性呼吸窘迫综合征（ARDS）患者使用恢复期血浆（CP）的临床疗效。
在土耳其开塞利市教育和研究医院进行的回顾性研究。
病例组由接受 CP 联合抗病毒和支持治疗的 COVID-19 所致 ARDS 成年患者（>18 岁）组成。将这些患者与仅接受抗病毒和支持治疗的患者进行比较。
在研究期间，共纳入 30 例 COVID-19 所致 ARDS 患者。11 例（36%）患者接受 CP 联合抗病毒和支持治疗，19 例（64%）患者在对照组中仅接受抗病毒和支持治疗。入院时，两组的中位年龄、人口统计学和临床数据以及初始实验室检查结果相似（P>0.05）。治疗第 14 天，两组的实验室值仍相似（P>0.05）。两组的死亡率无显著差异。
CP 治疗并未影响 COVID-19 合并 ARDS 患者的死亡率或临床转归。
